As we previously discussed (here and here), the biotech mergers and acquisitions market currently faces significant headwinds. These challenges include frozen capital markets, regulatory uncertainty at the Food and Drug...more
6/10/2025
/ Acquisitions ,
Biotechnology ,
Capital Markets ,
Corporate Governance ,
Department of Health and Human Services (HHS) ,
Food and Drug Administration (FDA) ,
Initial Public Offering (IPO) ,
Mergers ,
Pharmaceutical Industry ,
Securities and Exchange Commission (SEC) ,
Shareholders ,
Spinoffs ,
Tax Planning ,
Tax-Free Spin-Offs
On March 3, 2025, the Staff of the SEC Division of Corporation Finance expanded the categories of issuer that may submit draft registration statements confidentially for review by the SEC, effective immediately. Confidential...more